Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Data Examines Induction of Systemic Immune Response in Multiple Tumor Types

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Provectus Pharmaceuticals, Inc. announced details of a poster presentation on the induction of a systemic immune response with intralesional (IL) PV-10.

The poster entitled, "Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine Models of Breast Cancer and Melanoma," was presented by Shari Pilon-Thomas, Ph.D., Immunology Program, Moffitt Cancer Center.

Provectus’s PV-10, a 10% solution of Rose Bengal, is currently being examined as a novel cancer therapeutic. It is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. In melanoma patients, intralesional (IL) injection of PV-10 has led to regression of injected lesions as well as distant metastases (i.e., bystander lesions).

The Moffitt study examined the immunologic mechanism of PV-10 treatment in murine models of breast cancer and melanoma to determine how IL PV-10 therapy induces the systemic anti-tumor immune response apparent in bystander responses in clinical trial participants. In the current work, IL injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions in the MT-901 breast cancer model, with a significant increase in survival in mice treated with IL PV-10 versus those treated with IL saline. In a synchronous flank tumor/lung metastasis model, there was a significant reduction in lung metastases and subcutaneous tumor size in mice treated with IL PV-10 versus those treated with IL saline. Injection of PV-10 into the opposite, non-tumor bearing flank, did not affect the size of subcutaneous lesions nor the number of lung metastases. Splenocytes harvested from PV-10-treated mice exhibited tumor-specific enhancement of interferon-gamma production and cytotoxicity against the treated cell line, along with adoptive transfer of immunity upon implantation in naïve mice. A copy of the poster is available at the following link:

http://www.pvct.com/publications/SPTAACR2013-Final.pdf

Dr. Pilon-Thomas commented, “The findings of this study confirmed not only that PV-10 induces tumor-specific immunity after a single treatment with IL-PV-10 in multiple tumor types, but that the ablative process is critical for this in situ stimulation of the immune system. The data also show that T cells play a critical role in this response. We feel this is a promising direction for additional translational research that will further define the processes that occur systemically following PV-10 treatment.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Go-Between Immune Cell is Key to Priming the Body’s Fight Against Cancer
‘Antigen-presenting cell’ activates T cells by alerting them to the presence of tumors.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!